Sulfasalazine
- PDF / 230,846 Bytes
- 25 Pages / 504.57 x 720 pts Page_size
- 58 Downloads / 160 Views
Drugs 2005; 65 (13): 1825-1849 0012-6667/05/0013-1825/$39.95/0 © 2005 Adis Data Information BV. All rights reserved.
Sulfasalazine A Review of its Use in the Management of Rheumatoid Arthritis Greg L. Plosker and Katherine F. Croom Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: D. Aletaha, Division of Rheumatology, Department of Internal Medicine, University of Vienna, Vienna, Austria; B.A.C. Dijkmans, Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; S. Kawai, Division of Rheumatology, Toho University School of Medicine, Tokyo, Japan; T. Kennedy, Acute Medicine and Rheumatology, Royal Liverpool University Hospital, Liverpool, England; H. Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan. Data Selection Sources: Medical literature published in any language since 1980 on ‘sulfasalazine’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE search terms were ‘sulfasalazine’ or ‘sulphasalazine’ and ‘rheumatoid arthritis’. EMBASE search terms were ‘sulfasalazine’ or ‘sulphasalazine’ and ‘rheumatoid arthritis’. AdisBase search terms were ‘sulfasalazine’ or ‘sulphasalazine’ and ‘rheumatoid arthritis’. Searches were last updated 8 August 2005. Selection: Studies in patients with rheumatoid arthritis who received sulfasalazine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Sulfasalazine, rheumatoid arthritis, pharmacodynamics, pharmacokinetics, therapeutic use.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1826 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828 2. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828 2.1 Immunomodulatory Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828 2.1.1 In Vitro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828 2.1.2 In Vivo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828 2.2 Anti-Inflammatory Effects . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
